Beta Blocker Pharmacology

Molecular Mechanism of Beta Blockade

Cardiovascular Effects

• Chronotropic effect: Decreased heart rate through SA nodal depression and prolonged AV nodal conduction
• Inotropic effect: Reduced myocardial contractility and force of contraction
• Dromotropic effect: Slowed AV nodal conduction velocity, prolonged PR interval
• Blood pressure reduction: Decreased cardiac output and reduced renin-angiotensin-aldosterone system (RAAS) activity
• Coronary blood flow: Improved diastolic perfusion time and reduced myocardial oxygen demand

Receptor Selectivity and Agent Classification

• Preferentially block myocardial and juxtaglomerular apparatus receptors
• Include metoprolol, atenolol, bisoprolol, acebutolol, nebivolol
• Preserve β2-mediated bronchodilation at lower doses; lose selectivity at high doses

Non-selective beta blockers

• Block both β1 and β2 receptors equally
• Include propranolol, nadolol, timolol, pindolol
• Cause bronchospasm through β2 blockade in airways

Beta-3 selective agents

• Emerging class with potential metabolic benefits
• Nebivolol demonstrates mild β3 selectivity with nitric oxide-mediated vasodilation

Additional Pharmacological Properties

Intrinsic Sympathomimetic Activity (ISA)

• Agents with ISA (pindolol, acebutolol, carteolol) possess partial agonist activity
• Produce less bradycardia and may maintain or modestly increase heart rate at rest
• May be beneficial in bradycardic patients but less cardioprotective post-MI

Membrane-Stabilizing (Quinidine-like) Activity

• Propranolol, acebutolol, and oxprenolol possess local anesthetic properties
• Clinical significance remains marginal at therapeutic doses

Lipophilicity

• Lipophilic agents (propranolol, metoprolol, labetalol): CNS penetration, hepatic metabolism, variable bioavailability
• Hydrophilic agents (atenolol, nadolol): Renal excretion, predictable pharmacokinetics, minimal CNS effects, safer in renal disease

Alpha-Blocking Properties

• Provide additional vasodilation through α1-receptor antagonism
• Carvedilol additionally blocks β3 receptors with antioxidant properties
• Produce greater blood pressure reduction with less reflex tachycardia

Major Cardiovascular Indications

• Hypertension: Monotherapy or combination therapy for essential hypertension
• Coronary artery disease: Stable angina, acute coronary syndrome, post-MI cardioprotection
• Heart failure: Evidence-based therapy for HFrEF (β1-selective: metoprolol, bisoprolol; combined: carvedilol)
• Arrhythmias: Supraventricular tachycardia, atrial fibrillation rate control, ventricular arrhythmia suppression
• Hyperthyroidism: Beta-blockade of adrenergic symptoms
• Migraine prophylaxis: Propranolol, timolol, metoprolol
• Essential tremor: Propranolol first-line
• Anxiety and performance anxiety: Short-acting agents for acute situations
• Portal hypertension: Propranolol, nadolol, carvedilol for variceal bleeding prophylaxis
• Tetralogy of Fallot: Propranolol for hypercyanotic spells

Risk Factors for Adverse Effects

• Asthma/COPD: Increased bronchospasm risk with non-selective agents
• Diabetes mellitus: Impaired hypoglycemic awareness, prolonged hypoglycemia
• Peripheral arterial disease: Worsening claudication symptoms
• Severe bradycardia/AV block: Contraindication to initiation
• Decompensated heart failure: Relative contraindication; requires slow titration in HFrEF
• Pregnancy: Generally safe but some agents preferred (see complications)
• Hepatic impairment: Reduced metabolism of lipophilic agents

Desired Therapeutic Effects

• Reduced resting heart rate: Typically 10-25 bpm reduction from baseline
• Decreased blood pressure: Modest reduction (10-15 mmHg systolic) as monotherapy
• Angina relief: Decreased frequency and severity in coronary artery disease
• Improved exercise tolerance: Reduced dyspnea and chest discomfort on exertion
• Arrhythmia suppression: Regular rhythm restoration in SVT and rate control in atrial fibrillation

Adverse Effects (Patient-Reported Symptoms)

• Fatigue and weakness: Most common complaint; reduced cardiac output and cerebral perfusion
• Dizziness and lightheadedness: Orthostatic hypotension from excessive BP reduction
• Cold extremities and Raynaud's phenomenon: Unopposed α-adrenergic vasoconstriction
• Dyspnea and wheezing: Non-selective agents causing bronchospasm
• Sexual dysfunction: Erectile dysfunction in 10-25% of male patients; mechanism unclear
• Nightmares and vivid dreams: Lipophilic agents crossing blood-brain barrier
• Depression and mood changes: Particularly with higher doses
• Hypoglycemic unawareness: Masked adrenergic symptoms in diabetics
• Rebound hypertension and tachycardia: Abrupt discontinuation after prolonged use

Physical Examination Findings

• Bradycardia: Resting heart rate 50-60 bpm or lower
• Hypotension: Orthostatic drops >20 mmHg systolic or >10 mmHg diastolic
• Decreased cardiac output signs: Cool peripheral perfusion, prolonged capillary refill
• Bronchospasm: Expiratory wheezing on lung auscultation (non-selective agents)
• Slow AV nodal conduction: Distant S1, prolonged PR interval on ECG
• Reduced cardiac murmurs: Decreased intensity of systolic murmurs from reduced LV contractility

Pharmacological Classification Assessment

Agent-specific properties guiding selection

• Cardioselectivity: β1 selectivity ratio at therapeutic doses determines respiratory safety
• Lipophilicity: Determines metabolism route, CNS penetration, drug interactions
• ISA presence: Influences resting heart rate and hemodynamic profile
• Alpha-blocking activity: Predicts vasodilatory effects and antioxidant properties

Baseline and Monitoring Laboratory Parameters

• Baseline assessment: Serum creatinine (renal function), glucose (diabetes), electrolytes
• Heart rate and blood pressure: Response to titration; target HR 50-70 bpm, individualized BP targets
• ECG monitoring: PR interval (AV block development), QT interval (rare QT prolongation with some agents)
• Lipid panel: Beta blockers without ISA may increase triglycerides and reduce HDL
• Blood glucose: Baseline and periodic monitoring in diabetic patients
• Renal function: Critical for hydrophilic agents; dose adjustment if eGFR <30

Diagnostic Criteria for Drug Selection

• Highly selective: Bisoprolol (>340:1), Nebivolol (>340:1)
• Moderately selective: Metoprolol (145:1), Atenolol (74:1)
• Non-selective: Propranolol (1:1), Nadolol (1:1)

Pharmacokinetic Profile Interpretation

• Lipophilic agents: Absorption variable, hepatic metabolism (CYP2D6), half-lives 3-7 hours (require BID dosing) except propranolol long-acting formulations
• Hydrophilic agents: Predictable absorption, renal excretion, longer half-lives (atenolol 6-7 hours, nadolol 14-24 hours), once-daily dosing

Efficacy Monitoring

• Reduction in resting heart rate ≥10 bpm from baseline confirms β1 blockade
• Blood pressure reduction: expect 10-15 mmHg systolic and 5-10 mmHg diastolic
• Exercise capacity: inability to achieve target HR during stress testing indicates adequate blockade
• Arrhythmia control: regular rhythm on ECG/telemetry

Initial Selection Strategy by Indication

• Mechanism: Reduced cardiac output and RAAS suppression
• Preferred agents: β1-selective agents (metoprolol, atenolol, bisoprolol)
• Dosing: Metoprolol 25-50 mg BID, Atenolol 25-100 mg daily, Bisoprolol 5-20 mg daily
• Combination therapy: ACE inhibitors/ARBs or thiazide diuretics for additive BP reduction
• Expected outcomes: 10-15% reduction in BP; monotherapy success rate 40-50%

• Mechanism: Reduced myocardial oxygen demand, prolonged diastolic perfusion, ventricular remodeling prevention
• First-line: β1-selective agents (metoprolol, atenolol, bisoprolol)
• Acute phase: IV metoprolol 5 mg IV q5min x 3 doses, then oral 25-100 mg BID
• Maintenance: Target HR 50-60 bpm, continue indefinitely post-MI
• Special consideration: Carvedilol or labetalol if concomitant hypertension requires more aggressive control

• Mechanism: Slows disease progression, improves LV remodeling, reduces mortality by 30-35%
• Evidence-based agents only: Metoprolol succinate (extended-release), bisoprolol, carvedilol
• Note: Metoprolol tartrate (immediate-release) lacks HFrEF mortality benefit; must specify extended-release formulation
• Dosing strategy: Initiate low doses, uptitrate slowly over weeks (HF decompensation risk)
• Carvedilol: Start 3.125 mg daily, target 25 mg BID
• Metoprolol succinate: Start 12.5 mg daily, target 190 mg daily
• Bisoprolol: Start 1.25 mg daily, target 10 mg daily
• Contraindication: Acute decompensation; initiate only in euvolemic states
• Monitoring: Expect initial HR reduction and mild BP decrease; do not discontinue abruptly

Atrial Fibrillation Rate Control

• Mechanism: AV nodal slowing prolongs refractoriness
• Agents: Metoprolol, atenolol, diltiazem, verapamil (non-dihydropyridine CCBs preferred)
• Acute control: IV metoprolol 5 mg boluses or IV esmolol (ultra-short-acting) for acute settings
• Chronic maintenance: Oral metoprolol 25-200 mg daily divided
• Target resting HR: <110 bpm acceptable per 2019 ACC/AHA guidelines (previously <80 bpm)
• Note: Beta blockers do not convert AF to sinus rhythm; require anticoagulation regardless

Supraventricular Tachycardia

• Mechanism: AV nodal reentrant pathway slowing
• Agents: Same as atrial fibrillation
• Dosing: Metoprolol 25-100 mg TID
• Acute crisis: IV esmolol or IV propranolol 1-3 mg IV push

Hyperthyroidism (Symptomatic Management)

• Mechanism: Beta blockade without affecting thyroid hormone synthesis
• Agent: Propranolol (additional benefit: reduces T4→T3 peripheral conversion)
• Dosing: Propranolol 10-40 mg TID-QID; taper as euthyroidism achieved
• Duration: Temporary measure until PTU/methimazole/radioiodine takes effect
• Note: Not first-line thyroid-directed therapy

Migraine Prophylaxis

• Mechanism: Unknown; may involve β-adrenergic effects on cerebral vasculature
• Preferred agents: Propranolol (most evidence), timolol, metoprolol
• Dosing: Propranolol 80-240 mg daily in divided doses
• Timeline: 2-4 weeks for efficacy; requires 2-3 month trial before considering failure
• Efficacy: Reduces migraine frequency 40-50%

Essential Tremor

• First-line: Propranolol 40-120 mg BID
• Alternative if contraindicated: Primidone (anticonvulsant)
• Efficacy: 50-60% of patients achieve satisfactory tremor control

Titration Principles

• Gradual uptitration: Avoid sudden bradycardia/hypotension; allow 3-7 day intervals between dose increases
• Target endpoints: Individualize based on indication (HR 50-70 bpm for post-MI, <110 bpm for AF)
• Barrier to maximum dose: Hypotension (SBP <100 mmHg), bradycardia (<50 bpm), symptoms, or contraindications
• Combination therapy: More effective than monotherapy escalation; combine with ACE-I, ARB, CCB, or thiazide

Discontinuation Protocol

• Rebound hypertension: Increased BP 20-40 mmHg above baseline
• Rebound tachycardia: HR 20-40 bpm above baseline
• Acute coronary syndrome: Increased cardiac ischemia risk

Mechanism-linked toxicities

• Bradycardia and AV block: direct SA/AV nodal suppression; risk is multiplied when combined with non-dihydropyridine calcium channel blockers (verapamil, diltiazem), digoxin, amiodarone, or clonidine.
• Acute decompensated heart failure / cardiogenic shock: negative inotropy. The COMMIT trial showed excess cardiogenic shock when IV beta blockade was given early to MI patients with low output; ACC/AHA guidance is to withhold beta blockers in acute MI patients with signs of heart failure, hypoperfusion, or high shock risk and to start orally once stabilized.
• Bronchospasm: β2 blockade in airway smooth muscle. GOLD states cardioselective agents are not contraindicated in COPD and should not be withheld when cardiac indications exist; non-selective agents (including topical timolol eye drops) are the classic offenders in asthma.
• Hypoglycemia unawareness and blunted glycogenolysis: β2-mediated tremor and tachycardia are masked while diaphoresis is preserved — the ADA Standards of Care flag this in insulin-treated patients, but does not make beta blockers contraindicated.
• Peripheral vasoconstriction / Raynaud phenomenon: unopposed α1 tone; less prominent with vasodilating agents (carvedilol, labetalol, nebivolol).
• Dyslipidemia: agents without ISA raise triglycerides and lower HDL.
• QT prolongation and torsades: unique to sotalol (class III potassium-channel blockade) — requires renal dosing and monitored initiation.

Contraindications

• Symptomatic bradycardia, second-/third-degree AV block without a pacemaker, decompensated HF, cardiogenic shock.
• Untreated pheochromocytoma: beta blockade before alpha blockade causes unopposed α-mediated hypertensive crisis.
• Cocaine-associated chest pain: same unopposed-alpha concern; AHA favors benzodiazepines, nitrates, and phentolamine.
• Abrupt withdrawal: receptor upregulation causes rebound tachycardia, hypertension, and ischemia — always taper.

Overdose and reversal

• Glucagon: first-line antidote; activates cardiac adenylyl cyclase independent of the β receptor, raising cAMP. Give high-dose IV bolus followed by infusion; expect vomiting.
• Adjuncts: atropine, IV calcium, high-dose insulin euglycemic therapy, vasopressors, and transvenous pacing; sodium bicarbonate for QRS widening from propranolol's membrane-stabilizing sodium-channel effect. Lipid emulsion and ECMO are rescue options.

• Metoprolol succinate, not tartrate, in HFrEF: only metoprolol succinate (ER), bisoprolol, and carvedilol have mortality data. Beta blockade is one of four pillars of guideline-directed therapy in the 2022 AHA/ACC/HFSA guideline — ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor. A stem listing only three classes is testing whether you notice the missing SGLT2 inhibitor.
• Never start a beta blocker in decompensated heart failure: the single best next step in a volume-overloaded patient is diuresis, then initiate or continue beta blockade once euvolemic. Conversely, do not abruptly stop a chronic beta blocker during a mild HF exacerbation.
• Alpha before beta in pheochromocytoma: phenoxybenzamine first, beta blocker second. Giving propranolol first produces unopposed α-vasoconstriction and hypertensive crisis — the classic single-fact question.
• Propranolol in thyroid storm: blocks adrenergic symptoms and inhibits peripheral T4→T3 conversion. It does not treat the underlying thyroid gland — thionamide plus iodine (given after the thionamide) does.
• Bradycardia + hypotension + hypoglycemia = beta blocker overdose; bradycardia + hypotension + hyperglycemia = calcium channel blocker overdose. Antidote for the former is glucagon.
• Beta blockade blunts epinephrine in anaphylaxis: a patient on a beta blocker with refractory anaphylaxis gets glucagon after IM epinephrine 0.3 mg.
• Cardioselectivity is dose-dependent: high-dose metoprolol loses β1 selectivity and can provoke bronchospasm. Even topical timolol for glaucoma has caused fatal asthma exacerbations.
• Common distractor — uncomplicated hypertension: the 2017 ACC/AHA hypertension guideline lists thiazides, calcium channel blockers, and ACEI/ARBs as primary agents, reserving beta blockers for compelling indications (post-MI, HFrEF, rate control, angina). Choose a beta blocker when the stem supplies that indication, not for isolated blood pressure control.
• Atenolol is renally cleared — accumulates in CKD and is avoided in pregnancy in favor of labetalol; recall that all ACE inhibitors, including captopril, are contraindicated in pregnancy.